The Israeli firm said that it intends to file two investigational new drug applications, one from its stable of in-house drug candidates and one from a collaboration with Japan's Nitto Denko, in 2012.
In its amended preliminary prospectus, the firm said that through the first nine months of the year, it had sequenced the whole genomes of more than 400 individuals and has an order backlog of more than 800 genomes.
The firm, which also disclosed that it had undergone a 1-for-2 reverse stock split in September, had previously said its IPO could raise as much as $200 million.
The company hopes to raise up to $17.6 million in order to create a laboratory, to launch its lead platform, and to develop a second generation of the system.
The financial reporting manager being sought will help create "procedures to ensure that Regulus is fully compliant and ready to become a publicly traded organization," according to Regulus.
The company will use the cash infusion to expand its international market presence, with an emphasis on the US and Japan, where it is seeking regulatory approval for a number of multiplex PCR-based diagnostic tests.
In an amended S-1, the company which filed for an IPO in July, said its net loss rose to $12.6 million, and start-up costs increased seven-fold to $4.9 million.
